FCGY yields 2000000.00% · JNJ yields 2.13%● Live data
📍 FCGY pulled ahead of the other in Year 1
Combined, FCGY + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of FCGY + JNJ for your $10,000?
Forecastagility Corporation provides legacy application migration solutions to corporate clients in the United States and internationally. The company develops toolsets that migrate RPG and COBOL applications written for the IBM i-AS/400 environment to open platforms, such as Windows, Linux, or UNIX; and toolsets and services to modernize green screen applications for AS/400 and Mainframe environments. Its products include BABYi, a standard edition developer toolset and application server environment to migrate AS/400 RPG and COBOL applications to Windows; and BABY36 developer toolset, a suite of compilers, utilities, and operating system services that allow applications to be rehosted at the source code level, and recompiled and executed on the target platform. The company's products also comprise Infinite i, a suite of compilers, utilities, and operating system services that allow applications and programs to be migrated at the source code level, recompiled, and executed on the target platform; Infinite36 that migrates IBM System/36 RPG and COBOL applications to Windows, Linux, or UNIX; Infinite Cloud that create graphical screens from IBM i/AS400 green screens; and Infinite I Database Migration Tool for DB2 for IBM I (DB2/400) that enables to migrate IBM I, iSeries, and AS/400 data to Oracle or MS SQL environment. In addition, it offers migration and GUI creation services. The company was formerly known as Infinite Software Corporation and changed its name to Forecastagility Corporation in June 2019. Forecastagility Corporation was founded in 1975 and is based in Irvine, California.
Full FCGY Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.